The Daily Dose: Novartis’ data faking scandal keeps getting worse

Words matter. Images matter. The Scientific Inquirer needs your support. Help us pay our contributors for their hard work. Visit our Patreon page and discover ways that you can make a difference.

The Novartis’ Zolgensa data scandal continues spinning and it’s not in a good direction. More facts are coming to light that resulted in the pharmaceutical company admitting that it had submitted fake data to the Food and Drug Administration.

There’s lots of news coverage about the Johnson & Johnson guilty verdict in the Oklahoma opioids trial. The fact that the ruling went against the company constituted it as being a “landmark” decision. Unfortunately, the fine amounted to a slap on the wrist, if that. According to FiercePharma, “for J&J individually, the financial hit is minimal, some analysts pointed out; with sales coming in fast enough to total $81.6 billion in 2018, it would take the company about two and a half days to cover the verdict—if it’s forced to pay that much, or anything, after appeals.” Not only that, the company will be appealing and any payout will be years away and most likely further reduced.

Even in death, Jeffrey Epstein continues to ruin lives and institutions. In this case, it’s the Massachusetts Institute of Technology. After it emerged that the university accepted considerable donations from Epstein, faculty members began cutting ties with the school. The fallout continues. According to Nature, “The Massachusetts Institute of Technology (MIT) is launching an investigation into its interactions with sex offender and alleged sex trafficker Jeffrey Epstein. The university — one of the most prominent in the United States — received about US$800,000 in donations from the disgraced financier over two decades.”

IMAGE SOURCE: Creative Commons

Leave a Reply

%d bloggers like this: